Objective: Detailed characterization of progesterone and ovulation across the menopausal transition provides insight into conception risk and mechanisms of reproductive aging.
L uteal inadequacy is linked to reduced fecundity 1,2 ; thus, a great deal of attention has been paid to luteal function, as assessed by progesterone and its derivatives. Although progesterone levels during the luteal phase of the menstrual cycle seem to decline with advancing age, 3, 4 and frequency of ovulatory (O) cycles also declines with advancing age, 5, 6 the extent to which fecundity might be affected by these changes is not entirely clear. This lack of information is, in part, a result of the use of limited windows of observation of hormonal changes across the transition to menopause, with regard to both sampling frequency and length of follow-up. Most longitudinal studies of reproductive aging have monitored progesterone levels in serum specimens, thereby limiting sampling frequency and length of follow-up. 7Y12 Studies using urine specimens have both honed and broadened the window of observation by allowing for more frequent sampling 13 and longer periods of prospective monitoring. 14 Because the transition to menopause is associated with increasing average cycle length, 15<18 it is of particular interest to examine the hormonal and O status of long cycles. For example, although long cycles are often assumed to be anovulatory (AO), 19 few studies have, in fact, been designed to capture and describe the hormonal characteristics of long cycles. The few addressing this have focused on small samples of women who were 40 years or older. 14, 20, 21 There is thus a need for larger, detailed studies that include substantial numbers of long cycles to assess whether they are AO and how their hormonal characteristics compare with O cycles.
In addition to providing information on fecundity across the transition to menopause, detailed assessment of progesterone dynamics can provide insight into the underlying mechanisms of reproductive aging. Although there is a debate about whether the hypothalamus and pituitary or the gonads are the initial or dominant site contributing to hormonal and cycle changes in the perimenopause, 22 it is widely accepted that a declining pool of follicles plays a key role in the onset of menopause and that declining follicle quality is partly responsible for decreased fecundity beginning after age 30 years. 23 How either of these features of ovarian aging relate to changes in the perimenopause is not well understood, although elevated follicle-stimulating hormone (FSH), decreased inhibin B, and decreased antimüllerian hormone are believed to reflect a depleting pool of follicles. 24 One of our objectives is to interpret progesterone changes across the transition to menopause in light of these features of reproductive aging.
A challenge for studies on reproductive aging is the use of age as a comparative anchor across women. This has confounded studies of reproductive aging because women of similar ages can have very different hormonal levels 25 and because they undergo menopause across a broad range of ages. 26 Reproductive stages such as those put forth in the Staging Reproductive Aging Workshop (STRAW) system have been proposed as an alternative to age for research and clinical purposes. 27 In this study, we assess hormones by both reproductive stage and chronological age.
This study extends prior work on progesterone and reproductive aging to include longer windows of observation coupled with daily sampling for a relatively large sample of women. Our goal is to examine how progesterone levels and O status change across the transition to menopause in a 5year prospective study with daily urinary hormone measures. We use a reproductive staging system, based on variance in cycle length, 28<30 to monitor the transition to menopause. Our specific aims were to (1) assess the frequency and day of ovulation by age and reproductive stage; (2) compare FSH, luteinizing hormone (LH), and estrone-glucuronide (E1G) levels between O and nonovulatory cycles; and (3) estimate pregnanediol-3-glucuronide (PDG) levels in all cycles and O cycles by age and reproductive stage.
METHODS

Participants
This report used data collected as part of the Biodemographic Models of Reproductive Aging (BIMORA) project. 25 The BIMORA participants were recruited from the Tremin Research Program on Women's Health (TREMIN). BIMORA participants were either from the second cohort of women recruited into TREMIN in 1961 to 1963 or from women subsequently recruited into TREMIN after the second cohort but before 1997. 25 At the time of recruitment, TREMIN women eligible for BIMORA were between the ages of 25 and 60 years, had at least one intact ovary, and were not using any prescription reproductive hormones; pregnant or breast-feeding women and women receiving cancer treatment were not eligible. Details on sample recruitment are provided in Reference 25; briefly, of 748 women enrolled in TREMIN in 1997, 225 were eligible, and 156 ultimately participated in BIMORA. For this study, we excluded all data from participants with no uterus; data were also excluded for ambiguous bleed or cycle day information and for 3 months after exogenous hormone use, pregnancy, breast-feeding, miscarriage, major surgery, chemotherapy, or use of any medications known to affect reproductive hormone or menstrual bleed patterns. The final analysis sample comprised 108 women aged 25 to 58 years at recruitment and 64,671 woman-days of observation.
Participants provided written informed consent and were paid $150 per year for their participation. Procedures were approved by the institutional review boards of the University of Utah, the Pennsylvania State University, Georgetown University, and the University of Washington.
Data Collection
Daily first-morning urine specimens were collected from January 14 to July 15 of each year from 1998 to 2002. Daily information was collected on menstrual bleeding, major medical conditions and treatments, and all over-the-counter and prescription medication used. During the BIMORA project, most participants continued to record menstrual bleed data on calendar cards for TREMIN. We combined the TREMIN bleed data for July 16 to January 13 with the BIMORA data for January 14 to July 15 for each project year from 1998 to 2002; for 2002, however, we have only BIMORA bleed data. We thus have nearly complete menstrual cycle data for most participants for the 5-year period.
Height and weight for body mass index (BMI) come from a 2000 self-administered health survey, at the midpoint of the study. BMI was available for the year 2000 for 90 of the 108 women. For the remaining 18 women, all available BMI data from previous years for each woman were used in a linear mixed-effects model of BMI by year; we then used the estimated model to impute a value for the year 2000.
Laboratory methods
Urine specimens were assayed with an enzyme immunoassay (EIA) for PDG, a urinary metabolite of progesterone. 31 Interassay and intra-assay coefficients of variation (CVs) were 9.2% and 10.3%, and the EIA cross-reacted 100% with PDG, 119% with 20>-hydroxy-4-pregnen-3-one, 8.7% with pregnanediol, 2.7% with 20A-hydroxy-4-pregnen-3-one, and less than 1% with other progestins. The metabolites and crossreactants parallel the serum levels of progesterone. Urine specimens were also assayed for intact FSH, A-LH, and estrone conjugates using previously described and validated EIAs. 32, 33 E1G concentrations were statistically corrected for slight assay nonparallelism, using 1:5 as the dilution standard to which all values were corrected. 32 Hormone concentrations were estimated from optical density using a four-parameter logistic model (Biolinx 1.0; Dynex Laboratories, Inc., Chantilly, VA). Urine specimens were assayed in duplicate and adjusted by specimen specific gravity, using a mean specific gravity of 1.020. 34 
Reproductive stage determination
A reproductive stage was assigned to each menstrual cycle, using a four-category scale ( Table 1 ) derived from the STRAW recommendations. 27 Based on the criterion of variability in cycle length used by other researchers for defining the early and late stages of the transition to menopause, 28<30 we developed a unique approach using the CV of menstrual cycle length to assign reproductive stage.
Cycle length was calculated as the number of days from the first day of a menstrual bleed to the day before the next bleed. A menstrual bleed was defined as an interval with at least 2 days of bleeding in six consecutive days; the interval had to be preceded by at least five consecutive days of no bleeding.
A rolling cycle length CV (the SD of cycle length divided by the mean cycle length) was calculated for each cycle using the length of the current cycle and the five previous cycles. When fewer than five previous cycles were available, all cycle lengths observed before the current cycle were used.
Cutoff values for the rolling cycle length CV were chosen to represent stages similar to the STRAW system 27 (Table 1) .
Because CV values less than 20% represent fewer than 7 days of deviation from a 35-day cycle (considered the upper end of normal cycle length 35 ), we used it to indicate premenopause (stage j3). A 20% to 40% CV was chosen to represent the STRAW criterion of cycle length variance longer than 7 days (stage j2). A CV greater than 40% percent or the presence of a cycle longer than 60 days in length was used for the STRAW criterion of two or more skipped cycles (stage j1). Postmenopause (stage +1) was defined as 1 year with no menstrual bleeding; this stage was only included in analyses of PDG area under the curve (AUC).
Cycles that were right or left censored at fewer than 60 days within the 6-month period of urine collection each year and for which there was no cycle length information from TREMIN outside this 6-month period were assigned the stage occurring 60% or greater of the time within the 6month interval. Cycles censored at 60 or more days in length were assigned either stage j1 or +1; in some censored cycles, it was not possible to reliably differentiate between stages j1 and +1, but this occurred in only 11 of 3,303 menstrual segments.
Estimation of O status and day of ovulation
All complete cycles were evaluated for presence and timing of ovulation using a hierarchal algorithm, described in detail elsewhere. 36 In brief, to identify the presence or absence of ovulation, we used the algorithm for menstrual intervals by Kassam et al 37 , which calculates a ratio of daily PDG to the minimal 5-day moving average PDG to identify a sustained PDG rise. This approach avoids absolute threshold levels for defining the presence or absence of ovulation, given potential interwoman variation in the metabolism and excretion of progesterone. 37 Previously, we found that the method of Kassam et al 37 had 100% specificity and 100% sensitivity in a sample of 52 menstrual cycles including 25 perimenopausal cycles. 36 Censored cycles were inspected visually for the presence or absence of ovulation; evidence of a sustained elevation in PDG (more than four consecutive days) was taken as evidence of ovulation, whereas absence of a sustained rise in PDG was coded as having no evidence for ovulation, which was distinct from a cycle coded as AO. To estimate day of ovulation in complete cycles, we used a hierarchical algorithm, optimized for precision by prioritizing, first, the day of the midcycle LH peak; second, a midcycle FSH peak; third, a day of luteal transition; and, fourth, a modified version of a running PDG average. 36 This algorithm estimated day of ovulation within T2 days in 93% of a sample of 30 test cycles. 36 Censored cycles were kept for analyses if there was clear evidence of ovulation and sufficient hormonal information to estimate day of ovulation.
Statistical analyses
Hormonal data were log transformed before all analyses. In the analyses of O status, baseline and peak hormone levels, cycle length, and day of ovulation, the unit of analysis was the cycle. Cycles with fewer than 32 days and no evidence of ovulation were omitted; censored cycles longer than 32 days with no evidence of ovulation were treated as AO. To account for potential bias in this approach, analyses modeling anovulation were repeated excluding the latter set of cycles. Fifth percentile hormone levels were used to estimate baseline hormone levels in a cycle, whereas the 95th percentile was used to estimate peak hormone levels.
For analysis of total PDG exposure, the unit was the 6month interval; we calculated 6-month PDG AUC for daily PDG during the 6-month interval for each study year. If PDG data were missing for fewer than 7 consecutive days, AUC was interpolated. When more than 7 consecutive days were missing or data were missing at either end, AUC was computed without that segment, and the final result was weighted upward to represent the full 181-day span. If more than 30 days were missing data, the interval was excluded. To assess the relationship between total PDG exposure and stage, the stage occurring 60% or greater of the time within the 6-month segment was assigned for the interval; if the most prevalent stage occurred less than 60% of the time, the interval was coded as a mixed stage; this stage was assigned to 39 of the 359 6-month intervals.
Tables were constructed, summarizing the demographic characteristics of the study population, the proportion of O cycles by reproductive stage and cycle length (960 or G60 d), and cycle characteristics by O status. Generalized linear mixed-effects models were used to determine the association between likelihood of an AO cycle and both age and reproductive stage. Linear mixed-effects models were used to compare cycle length and hormonal characteristics between O and AO cycles, while adjusting for age and stage: the median and 5th and 95th percentiles were compared for E1G, LH, and FSH. Day of ovulation, PDG AUC, and, in O cycles, PDG median and 5th and 95th percentiles were each examined for associations with age and stage. Linear and quadratic associations between age and PDG were tested. To separate effects due to between-participant differences in age from within-participant aging occurring across the study, age was modeled as two separate terms: age at study entry and years followed. All analyses were repeated with adjustment for BMI.
Statistical analyses were done using R 2.6.1. 38
RESULTS
Demographic data were available for most of the 108 BIMORA participants and were derived from the 2000 selfadministered survey or previous TREMIN surveys. All women in BIMORA are whites. More than 80% of the 108 women completed a college or postgraduate degree, 62% had no evidence of ever smoking, 6% were current smokers, 33% had unknown parity, 32% had two live births, 19% had three or four live births, and the remainder had one live birth. Because of missing data, these variables were not used in analyses. Age by reproductive stage is shown in Table 2 ; note that this was derived using the 6-month stage assigned to women, and thus, women can be represented in multiple stages. The mean (SD) and median BMI for the sample of 108 women were 24.2 (5.1) and 23.2 kg/m 2 , respectively. Seventy percent of the BMIs were below 25 kg/m 2 (normal), 18% fell between 25 and 29 kg/m 2 (overweight), and 12% were 30 kg/m 2 or greater (obese). Figure 1 is a flowchart of sample sizes of women and cycles used in the analyses. Cycles that were right or left censored at fewer than 32 days were omitted from analyses including hormones because of insufficient information to estimate hormonal percentiles. Table 3 shows the percentage of all O and all AO cycles that fell within each reproductive stage. Most AO cycles (65%) fell into the late perimenopause (j1) stage, whereas most O cycles (70%) fell into the premenopause (j3) stage. Between-participant age effects and within-participant age effects were similar in their relationship to O status, so these effects were combined, and age was modeled as a . In linear mixed-effects models using 1,592 cycles from 90 women, both higher age and more advanced reproductive stage were associated with a greater rate of AO cycles (P G 0.0001 for both): of the two covariates, stage was a stronger predictor, with the rate of AO cycles progressively increasing from stages j3 to j2 to j1; the likelihood of AO cycles increased with age only after age 45 years. Figure 2 illustrates the probability of an AO cycle with age in the left panel and the proportion of AO cycles across age by reproductive stage in the right panel. These results were unchanged when the 99 censored cycles (those 932 d and having no evidence of ovulation) were excluded. Mean BMI for women with AO cycles was lower than for women with O cycles: of 1,592 cycles, the mean (SD) BMI for women with O cycles was 24.5 (5.9) kg/m 2 and the mean BMI for women with AO cycles was 23.6 (5.0) kg/m 2 . Note that the same women can be in both the O and AO groups for different cycles. This difference in BMI by O status is borderline significant (P = 0.05) when adjusted for stage and age. However, adding BMI in the model did not alter the association between AO status and age or stage.
Mean and median day of ovulation were progressively later, with larger SDs, for each successive reproductive stage ( Fig. 3 ). Mean (SD) and median cycle days of ovulation were 15 (4) and 14 for stage j3, 17 (8) and 15 for stage j2, and 27 (25) and 17 for stage j1. Day of ovulation was significantly later in stage j1 than in the other stages (P G 0.0001). Day of ovulation was not associated with within-participant aging (P = 0.076). Adjustment for BMI did not change these results.
Cycle length was significantly longer for AO than O cycles (Table 3) irrespective of adjustment for BMI. Although AO cycles were longer than O cycles, there were still numerous long O cycles. We examined this in more detail by tabulating the frequency of ovulation in cycles that were longer than 60 days. Of a total of 1,699 cycles (complete and censored) assessed for O status, 115 (7%) were greater than 60 days. Of these 115 segments, 29 (25%) were O, whereas 29 (25%) were AO. The remaining 57 (50%) were indeterminate; that is, no evidence for ovulation was observed, but hormone data were not available for a full segment from menses to menses. Thus, at least one quarter of all cycles longer than 60 days were ultimately O. Figure 4 shows illustrative examples of long O and AO cycles in stage j1 women aged 46 and 55 years.
Comparison of hormonal and cycle length characteristics between AO and O cycles used 1,336 cycles. The results are shown in Table 3 . All indicators (median and 5th and 95th percentiles) show that FSH and LH levels were higher and E1G levels lower in AO versus O cycles. These results remained unchanged after adjustment for BMI.
Based on 358 6-month intervals from 108 women (103, stage j3; 17, stage j2; 70, stage j1; 134, stage 1; and 34, mixed stage), there were significant differences in mean PDG AUC by stage (P G 0.0001) while adjusting for both between-participant and within-participant age. Mean PDG AUC significantly decreased from stages j3 and j2 to j1, then to stage +1 (P G 0.0001 for each difference), with no significant differences among stages j3 and j2 and a mixed stage (Fig. 5) . The relationship between PDG AUC and age-at-study entry was mainly linear, with PDG AUC decreasing across participant age. There was a significant interaction between stage and within-participant age, with mean PDG AUC decreasing as participants aged in stages j1 and j2. There was no consistent association between withinparticipant age and PDG AUC for stage j3. These results remained unchanged with adjustment for BMI.
PDG indicators from O cycles are shown by reproductive stage in Table 4 . Ninety-fifth percentile averages declined linearly from stages j3 to j1 (P = 0.023). In contrast, the median and fifth percentile averages increased from stages j3 to j2 (P = 0.2 and P G 0.01, respectively). Median, but not fifth percentile, levels were ultimately lower in stage j1 than stage j3 (P = 0.011).
DISCUSSION
Using prospectively collected daily hormone data from more than 1,000 cycles, we found that significant increases in anovulation and decreases in PDG did not occur until women were in late perimenopause (stage j1). Most cycles (960%) in the late perimenopause were AO, but 25% of cycles longer than 60 days were O. Thus, exposure to the risk of conception, theoretically, is far from negligible in women experiencing cycles long enough to classify them as late perimenopausal. Moreover, we found that day of ovulation increased, on average, as women progressed through the transition to menopause. Together, these findings support that women and clinicians should not rely on cycle length in perimenopause as a benchmark for identifying whether or not a cycle is O or for pinpointing a fertile period of the menstrual cycle. 13, 39 As expected, anovulation increased as women progressed through the transition to menopause. Although the probability of anovulation increased with age after the age of 45 years, reproductive stage was a stronger predictor than age of the probability of anovulation (Fig. 2) . However, there were very few AO cycles in women younger than 40 years: of 1,592 cycles, only 16 of the AO cycles were in women younger than 40 years. The few studies that have examined changes in O frequency in perimenopausal women did not use a formal staging system. The two most consistent findings in these studies, however, are, first, that anovulation increases as women progress through the perimenopause 13, 40, 41 and, second, that anovulation tends to be more common in longer cycles. 13, 42 Our results concur with these findings.
PDG AUC and O median and 95th percentile PDG declined by the late perimenopause (stage j1). Previously, we showed that average PDG slowly declined with age 25 ; here we show that this is only the case for women classified as being in the menopausal transition (stages j2 and j1); women classified as pretransitional (stage j3) did not experience declining PDG AUC with age. Reproductive stage was a more useful predictor than chronological age of PDG AUC; in recent work, we similarly found that stage was more useful than age as a predictor of E1G AUC levels. Our finding that PDG declined late in the transition to menopause is concordant with the many studies that have reported declining progesterone with increasing age or advancement of perimenopause. 7,8,13,20,21,25,40,43<45 However, our study disentangled the effects of reproductive stage and age. Only one other study has examined progesterone changes with well-defined reproductive stages: Hale et al 11 found that mean luteal phase serum progesterone was not significantly different across stages of the transition until the late menopausal transition.
Given that progesterone and progesterone metabolite levels are implicated in the etiology of breast cancer, 46 which increases through the perimenopausal years up to at least 60 years of age, 47 our observation that total progesterone exposure (PDG AUC) does not decline until late in the transition to menopause (stage j1; Fig. 5 ) may be informative for research on the prevention and control of breast cancer. It is likely that declining PDG AUC in the late perimenopause is largely a function of increased anovulation. Although this provides useful information on total progesterone exposure, it does not address whether luteal function is also declining across the transition. We therefore examined PDG levels in O cycles.
We found that median and 5th percentile levels of PDG in O cycles did not decline until late in the transition, but 95th percentile averages declined linearly across the transition to menopause. These results indicate that peak PDG in O cycles declines first (stage j2) and is followed in the next stage by declining PDG AUC, declining O median and fifth percentile PDG, and increasing anovulation. Our results are generally consistent with other studies examining luteal function across the transition to menopause. Miro et al 14 prospectively examined PDG levels in a sample of 34 perimenopausal women and found a progressive decline in PDG associated with cycles showing evidence of delayed follicular development; they suggested that this was indicative of a luteal phase defect. Santoro et al 13 reported a significant decrease in PDG in O cycles across 3 years in perimenopausal women and attributed this to declining follicle quality. Thus, declining progesterone across the menopausal transition is likely to be a function of both increasing anovulation and declining luteal secretion, which together support a model of declining follicle competency. 23 Evidence from studies of fetal loss and in vitro fertilization supports the fact that oocyte quality monotonically declines with age after the late 20s. 23, 48 We suggest that decreased PDG in O cycles and increasing anovulation with reproductive aging could be later stage manifestations of this process.
The average day of ovulation increased progressively from stage j3 to j1 (Fig. 3) . We also found that at least one quarter of cycles 60 days or longer were ultimately O. We chose to examine more closely only cycles longer than 60 days because that was the cutoff used in the original STRAW staging system as well as the one we used here for late perimenopause. Metcalf et al 21 similarly reported that long cycles were frequently O: in a study of 31 perimenopausal women, they found that 32% of cycles longer than 50 days in length were O. We are not aware of other studies that have examined the timing of ovulation with respect to age or reproductive stage. Increasingly delayed ovulation is consistent with a model of follicular depletion across the life span that predicts increasing delays in follicular development across the transition to menopause. 49 This model predicts that a natural outcome of a negative exponential process, which characterizes follicular depletion across the life span, is stochastically occurring periods of ovarian inactivity (ie, delayed follicular development and therefore delayed ovulation) as the follicle pool approaches exhaustion. 49 In contrast to our focus on follicular depletion as an explanatory mechanism for delayed follicular development and ovulation in the perimenopause, Miro et al 14 favor a Brefractory follicle[ model to explain delayed follicular development, placing primacy on follicle quality. In support of their model, they found reduced PDG in cycles with delayed follicular development; however, E1G was higher in these cycles, suggesting that this aspect of follicle health was not compromised. Thus, currently, it is not clear whether increasingly delayed ovulation reflects changing follicle quality and/or follicle quantity in models of reproductive aging.
Our observations of the hormonal characteristics of O and AO cycles are also consistent with both models of reproductive aging. We found higher LH and FSH and lower E1G in AO cycles when compared with O cycles. Higher LH and FSH in AO cycles have been observed in other studies. 11, 13, 40 Elevated gonadotropins in AO cycles are consistent with loss of negative feedback from delayed ovarian activity 49 ; this occurs early in a cycle and would thus be observable across the different sampling designs in these studies. The studies differ, however, with respect to estrogen: Santoro et al 13 Our study has several limitations. The BIMORA sample is biased toward women who chose not to use either hormone therapy as they went through the menopausal transition or oral contraceptives to prevent pregnancy. In addition, the sample consists primarily of white, middle-class, collegeeducated, and nonobese women. 25 Our results may therefore not be applicable to all women.
The BIMORA sample is likely to be biased toward women with later ages at menopause: TREMIN cohort II women with early ages at menopause completed the transition to menopause before the start of BIMORA in 1998. In a study of an earlier cohort of TREMIN women, Lisabeth et al 28 found that although the pattern of perimenopausal change in cycle length mean and SD did not differ by age at menopause, women with later menopause had longer, more variable cycles during the transition than those menopausal before 52 years of age.
We confined urinary hormone data collection to the same months of each year for all women to avoid confounding by potential seasonal variation in reproductive function; however, this design also obscures any potential circum-annual variation in patterns of reproductive aging. 50 Another limitation of our study is our single midstudy measure of BMI, derived from participant reports of weight and height. The pattern of bias commonly found for self-reports of height and weight is slight but can result in overestimates of lower BMI and underestimates of higher BMI. 51, 52 Most studies find that obesity has a dampening effect on ovulation, reproductive hormones, and fecundity. 13,53<57 In contrast, we found that AO cycles were weakly associated with slightly lower, not higher BMI, while controlling for age and stage. Progesterone and PDG have been found to be lower in overweight and obese women (BMI, 925 kg/m 2 ) compared with women of normal weight. 13, 55, 58 Although adding BMI did not alter the results of any of our analyses, our midpoint estimate may not be an accurate representation across the study period, particularly given that BMI has been found in other studies to increase across the transition to menopause. 59, 60 Our results are nevertheless consistent with other studies that found a decrease in O cycles and progesterone levels with progression through the menopausal transition, while controlling for clinically assessed annual BMI. 13, 41 The variance in cycle length we chose as cutoffs for each reproductive stage could have been determined in a different manner. Our goal was to operationalize the STRAW system for use with a large collection of cycle data. Like the methods tested by Harlow and colleagues, 28<30 our approach replicated the spirit of the original STRAW system, designed to be used by women, clinicians, and researchers alike. We note that our stage j3, premenopause, was based solely on variation in cycle length, but in the STRAW staging system, FSH levels are used to subdivide women without cycle length variation into premenopausal and perimenopausal stages. 27 Thus, our j3 stage likely includes cycles that would be classified as perimenopausal based on FSH levels. Our aim here was to use only nonhormonal criteria to classify cycles into reproductive stages so that we could assess the hormonal characteristics of those stages.
CONCLUSIONS
Anovulation increased and PDG AUC decreased in the late perimenopause (stage j1), when cycles were quite variable and frequently long. Day of ovulation also increased across the transition and was significantly later in the late perimenopause (stage j1) than in the premenopausal stage (stage j3). The long cycles characteristic of the late transition were AO more often than not (65% of all AO cycles occurred in stage j1), but up to 25% of stage j1 cycles 60 days or longer were ultimately O. These findings reiterate previous work suggesting that women and clinicians should not rely on cycle length in the perimenopause as a benchmark for identifying whether a cycle is O or for pinpointing a fertile period of the menstrual cycle. 13, 39 Reproductive stage is more informative than chronological age with respect to the likelihood of anovulation and changing PDG levels across the transition to menopause. Delayed ovulation in long cycles as the menopausal transition progresses is consistent with models of both declining follicle quantity and quality. Increasing anovulation and decreasing O PDG across the transition are consistent with declining follicle quality and may reflect late-stage manifestations of declining follicle competence beginning decades earlier.
